Efekty leczenia iniekcjami doszklistkowymi ranibizumabu w ramach grupy terapeutycznej B02 pacjentów z wysiękową postacią zwyrodnienia plamki związanego z wiekiem
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2015
Słowa kluczowe:
AMD, ranizumab, czynnik wzrostu śródbłonka naczyń, leczenie anty-VEGF
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wprowadzenie do medycyny leków hamujących angiogenezę porównywane jest do ery wprowadzenia antybiotyków w XX w. Udostępnienie w Polsce we wrześniu 2010 r. w ramach refundacji NFZ najnowocześniejszej i dotychczas najbardziej skutecznej terapii wysiękowej postaci zwyrodnienia plamki związanego z wiekiem z zastosowaniem iniekcji doszklistkowych przeciwciała monoklonalnego anty-VEGF (ranibizumab) wprowadziło nowe standardy leczenia. W niniejszym artykule podjęliśmy próbę oceny efektów leczenia w postaci wysiękowej AMD w ramach grupy terapeutycznej B02.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Fabrykiewicz-Rogalska MW, Kucharczuk J, Małolepszy Z, Malukiewicz G. Efekty leczenia iniekcjami doszklistkowymi ranibizumabu w ramach grupy terapeutycznej B02 pacjentów z wysiękową postacią zwyrodnienia plamki związanego z wiekiem. Ophthatherapy [Internet]. 31 marzec 2015 [cytowane 22 listopad 2024];2(1):56-4. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/617
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Fine SL, Berger JW, Maguire MG et al. Age-related macular degeneration. N Engl J Med. 2000; 342(7): 483-92.
2. Van Newkirk MR, Nanjan MB, Wang JJ et al. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology. 2000; 107(8): 1593-600.
3. Singer MA, Awh CC, Sadda S et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012; 119(6): 1175-83.
4. Brown DM, Michels M, Kaiser PK et al.; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116: 57-65.
5. Rosenfeld PJ, Brown DM, Heier JS et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1419-31.
6. Holz G, Amoaku W, Donate J et al. Safety and efficacy of flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophtalmology. 2011; 118(4): 663-71.
7. Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43-58.
8. Larsen M, Schmidt-Erfurth U, Lanzetta P et al.; MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012; 119(5): 992-1000.
9. Kaiser PK, Boyer DS, Cruess AF et al.; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012; 119(5): 1001-10.
10. Tano Y, Ohji M; EXTEND-I Study Group. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol. 2011; 89(3): 208-17.
11. Chakravarthy U, Harding SP, Rogers CA et al.; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900): 1258-67.
12. Ho AC, Busbee BG, Regillo CD et al.; HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014; 1(11): 2181-92.
13. Veselý P, Synek S. Repeatability and reliability of the visual acuity examination on logMAR ETDRS and Snellen chart. Cesk Slov Oftalmol 2012; 68(2): 71-5.
14. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity 100 measurements. Retina. 2010; 30(7): 1046-50.
15. Carneiro AM, Mendonça LS, Falcão MS et al. Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol. 2012; 6: 1149-57.
16. Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc. 2009; 107: 311-24.
17. Lim LA, Frost NA, Powell RJ et al. Comparison of the ETDRS logMAR, compact reduced logMar’ and Snellen charts in routine clinical practice. Eye (Lond). 2010; 24(4): 673-7.
18. Lalwani GA. All about PRONTO: study yielded good results in AMD with treatment guided by OCT. Retina Today. 2007; 41-8.
19. Boyer DS, Heier JS, Brown DM et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009; 116(9): 1731-9.
20. Canan H, Sızmaz S, Altan-Yaycıoğlu R et al. Visual outcome of intravitreal ranibizumab for exudative age related macular degeneration: timing and prognosis. Clin Interv Aging. 2014; 9: 141-5.
21. Arias L, Roman I, Masuet-Aumatell C et al. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina. 2011; 31(7): 1261-7.
22. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364: 1897-908.
23. Holz F, Bandello F, Gilies M et al.; LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophtalmol. 2013; 97(9): 1161-7.
24. Rauch R, Weingessel B, Maca SM et al. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration. Retina. 2012; 32(7): 1260-4.
25. Praca zbiorowa. Wytyczne leczenia wysiękowej postaci AMD lekiem Lucentis (ranibizumab). Okulistyka. 2012; wyd. specjalne, luty : 7-11.
26. Klein ML, Jorizzo PA, Watzke RC. Growth features of choroidal neovascular membranes in age-related macular degeneration. Ophthalmology. 1989; 96: 1416-9.
27. Lim JH, Wickremasinghe SS, Xie J et al. Delay to treatment and visual outcomes in patients treated with anti vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012; 153(4): 678-86.
2. Van Newkirk MR, Nanjan MB, Wang JJ et al. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology. 2000; 107(8): 1593-600.
3. Singer MA, Awh CC, Sadda S et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012; 119(6): 1175-83.
4. Brown DM, Michels M, Kaiser PK et al.; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116: 57-65.
5. Rosenfeld PJ, Brown DM, Heier JS et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1419-31.
6. Holz G, Amoaku W, Donate J et al. Safety and efficacy of flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophtalmology. 2011; 118(4): 663-71.
7. Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43-58.
8. Larsen M, Schmidt-Erfurth U, Lanzetta P et al.; MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012; 119(5): 992-1000.
9. Kaiser PK, Boyer DS, Cruess AF et al.; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012; 119(5): 1001-10.
10. Tano Y, Ohji M; EXTEND-I Study Group. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol. 2011; 89(3): 208-17.
11. Chakravarthy U, Harding SP, Rogers CA et al.; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900): 1258-67.
12. Ho AC, Busbee BG, Regillo CD et al.; HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014; 1(11): 2181-92.
13. Veselý P, Synek S. Repeatability and reliability of the visual acuity examination on logMAR ETDRS and Snellen chart. Cesk Slov Oftalmol 2012; 68(2): 71-5.
14. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity 100 measurements. Retina. 2010; 30(7): 1046-50.
15. Carneiro AM, Mendonça LS, Falcão MS et al. Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol. 2012; 6: 1149-57.
16. Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc. 2009; 107: 311-24.
17. Lim LA, Frost NA, Powell RJ et al. Comparison of the ETDRS logMAR, compact reduced logMar’ and Snellen charts in routine clinical practice. Eye (Lond). 2010; 24(4): 673-7.
18. Lalwani GA. All about PRONTO: study yielded good results in AMD with treatment guided by OCT. Retina Today. 2007; 41-8.
19. Boyer DS, Heier JS, Brown DM et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009; 116(9): 1731-9.
20. Canan H, Sızmaz S, Altan-Yaycıoğlu R et al. Visual outcome of intravitreal ranibizumab for exudative age related macular degeneration: timing and prognosis. Clin Interv Aging. 2014; 9: 141-5.
21. Arias L, Roman I, Masuet-Aumatell C et al. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina. 2011; 31(7): 1261-7.
22. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364: 1897-908.
23. Holz F, Bandello F, Gilies M et al.; LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophtalmol. 2013; 97(9): 1161-7.
24. Rauch R, Weingessel B, Maca SM et al. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration. Retina. 2012; 32(7): 1260-4.
25. Praca zbiorowa. Wytyczne leczenia wysiękowej postaci AMD lekiem Lucentis (ranibizumab). Okulistyka. 2012; wyd. specjalne, luty : 7-11.
26. Klein ML, Jorizzo PA, Watzke RC. Growth features of choroidal neovascular membranes in age-related macular degeneration. Ophthalmology. 1989; 96: 1416-9.
27. Lim JH, Wickremasinghe SS, Xie J et al. Delay to treatment and visual outcomes in patients treated with anti vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012; 153(4): 678-86.